Keros TherapeuticsKROS
KROS
About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Employees: 160
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
747% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $528K
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
38% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 47
38% more capital invested
Capital invested by funds: $1.47B [Q2] → $2.03B (+$559M) [Q3]
8% more funds holding
Funds holding: 151 [Q2] → 163 (+12) [Q3]
3.87% more ownership
Funds ownership: 89.29% [Q2] → 93.16% (+3.87%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
32%
upside
Avg. target
$42
270%
upside
High target
$111
874%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Piper Sandler Joseph Catanzaro 30% 1-year accuracy 10 / 33 met price target | 32%upside $15 | Overweight Maintained | 17 Jan 2025 |
Wedbush Andreas Argyrides 27% 1-year accuracy 6 / 22 met price target | 32%upside $15 | Neutral Downgraded | 17 Jan 2025 |
Scotiabank Greg Harrison 45% 1-year accuracy 13 / 29 met price target | 260%upside $41 | Sector Outperform Maintained | 16 Jan 2025 |
Oppenheimer Andreas Argyrides 27% 1-year accuracy 6 / 22 met price target | 102%upside $23 | Outperform Maintained | 16 Jan 2025 |
Truist Securities Srikripa Devarakonda 36% 1-year accuracy 12 / 33 met price target | 277%upside $43 | Buy Maintained | 23 Dec 2024 |
Financial journalist opinion
Based on 65 articles about KROS published over the past 30 days
Neutral
Accesswire
1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
2 days ago
Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
Accesswire
3 days ago
KROS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Keros Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
3 days ago
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
GlobeNewsWire
3 days ago
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time.
Neutral
Accesswire
4 days ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Keros Therapeutics, Inc. (KROS)
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
Accesswire
4 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
Neutral
Accesswire
5 days ago
Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Neutral
PRNewsWire
5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™